Probing the mechanism of reduced in vivo potency of insulin detemir
. (Source: Expert Opinion on Drug Metabolism and Toxicology)
Source: Expert Opinion on Drug Metabolism and Toxicology - June 5, 2023 Category: Drugs & Pharmacology Authors: Christian Lehn Brand Jeppe Sturis Source Type: research
Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades
CONCLUSION: Both glargine formulations are largely comparable to other basal insulins in terms of glucose-lowering properties in T1DM. Further, risk of hypoglycemia is lower with Gla-100 than Neutral Protamine Hagedorn but comparable to insulin detemir.PMID:36896906 | DOI:10.2174/1573399819666230310150905 (Source: Current Diabetes Reviews)
Source: Current Diabetes Reviews - March 10, 2023 Category: Endocrinology Authors: Banshi Saboo Hemraj Chandalia Sujoy Ghosh Jothydev Kesavadev Ips Kochar K M Prasannakumar Archana Sarda Ganapathi Bantwal R N Mehrotra Madhukar Rai Source Type: research
Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades
CONCLUSION: Both glargine formulations are largely comparable to other basal insulins in terms of glucose-lowering properties in T1DM. Further, risk of hypoglycemia is lower with Gla-100 than Neutral Protamine Hagedorn but comparable to insulin detemir.PMID:36896906 | DOI:10.2174/1573399819666230310150905 (Source: Current Diabetes Reviews)
Source: Current Diabetes Reviews - March 10, 2023 Category: Endocrinology Authors: Banshi Saboo Hemraj Chandalia Sujoy Ghosh Jothydev Kesavadev Ips Kochar K M Prasannakumar Archana Sarda Ganapathi Bantwal R N Mehrotra Madhukar Rai Source Type: research
Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades
CONCLUSION: Both glargine formulations are largely comparable to other basal insulins in terms of glucose-lowering properties in T1DM. Further, risk of hypoglycemia is lower with Gla-100 than Neutral Protamine Hagedorn but comparable to insulin detemir.PMID:36896906 | DOI:10.2174/1573399819666230310150905 (Source: Current Diabetes Reviews)
Source: Current Diabetes Reviews - March 10, 2023 Category: Endocrinology Authors: Banshi Saboo Hemraj Chandalia Sujoy Ghosh Jothydev Kesavadev Ips Kochar K M Prasannakumar Archana Sarda Ganapathi Bantwal R N Mehrotra Madhukar Rai Source Type: research
Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades
CONCLUSION: Both glargine formulations are largely comparable to other basal insulins in terms of glucose-lowering properties in T1DM. Further, risk of hypoglycemia is lower with Gla-100 than Neutral Protamine Hagedorn but comparable to insulin detemir.PMID:36896906 | DOI:10.2174/1573399819666230310150905 (Source: Current Diabetes Reviews)
Source: Current Diabetes Reviews - March 10, 2023 Category: Endocrinology Authors: Banshi Saboo Hemraj Chandalia Sujoy Ghosh Jothydev Kesavadev Ips Kochar K M Prasannakumar Archana Sarda Ganapathi Bantwal R N Mehrotra Madhukar Rai Source Type: research
Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Clin Ther. 2022 Nov;44(11):1520-1533. doi: 10.1016/j.clinthera.2022.09.012. Epub 2022 Oct 28.ABSTRACTPURPOSE: The goal of this study was to compare the efficacy and tolerability of insulin degludec with those of other long-acting insulin analogues (insulin glargine and insulin detemir) in patients with type 1 or 2 diabetes mellitus (T1D or T2D).METHODS: Those randomized controlled trials comparing insulin degludec with other long-acting insulin analogues in the treatment of patients with T1D or T2D published on or before August 21, 2022, were retrieved from PubMed, Web of Science, the Cochrane Library, and EMBASE. The effi...
Source: Clinical Therapeutics - February 10, 2023 Category: Drugs & Pharmacology Authors: Zhi-Yuan Dong Ji-Hua Feng Jian-Feng Zhang Source Type: research
Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Clin Ther. 2022 Nov;44(11):1520-1533. doi: 10.1016/j.clinthera.2022.09.012. Epub 2022 Oct 28.ABSTRACTPURPOSE: The goal of this study was to compare the efficacy and tolerability of insulin degludec with those of other long-acting insulin analogues (insulin glargine and insulin detemir) in patients with type 1 or 2 diabetes mellitus (T1D or T2D).METHODS: Those randomized controlled trials comparing insulin degludec with other long-acting insulin analogues in the treatment of patients with T1D or T2D published on or before August 21, 2022, were retrieved from PubMed, Web of Science, the Cochrane Library, and EMBASE. The effi...
Source: Clinical Therapeutics - February 10, 2023 Category: Drugs & Pharmacology Authors: Zhi-Yuan Dong Ji-Hua Feng Jian-Feng Zhang Source Type: research
Rate of Inpatient Hypoglycemia Following a 1:1 Dose Interchange Between Concentrated Insulin Glargine to Insulin Detemir
CONCLUSION AND RELEVANCE: A 1:1 unit interchange from iGlar300 to iDet100 led to a higher incidence of hypoglycemic events compared to those interchanged from iGlar100. Dose reduction should be considered when transitioning from home iGlar300 to iDet100 in the inpatient setting.PMID:35993253 | DOI:10.1177/10600280221119187 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 22, 2022 Category: Drugs & Pharmacology Authors: S D Wulfe K M Janzen J Addison D Kelley Source Type: research
Rate of Inpatient Hypoglycemia Following a 1:1 Dose Interchange Between Concentrated Insulin Glargine to Insulin Detemir
CONCLUSION AND RELEVANCE: A 1:1 unit interchange from iGlar300 to iDet100 led to a higher incidence of hypoglycemic events compared to those interchanged from iGlar100. Dose reduction should be considered when transitioning from home iGlar300 to iDet100 in the inpatient setting.PMID:35993253 | DOI:10.1177/10600280221119187 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 22, 2022 Category: Drugs & Pharmacology Authors: S D Wulfe K M Janzen J Addison D Kelley Source Type: research
Rate of Inpatient Hypoglycemia Following a 1:1 Dose Interchange Between Concentrated Insulin Glargine to Insulin Detemir
CONCLUSION AND RELEVANCE: A 1:1 unit interchange from iGlar300 to iDet100 led to a higher incidence of hypoglycemic events compared to those interchanged from iGlar100. Dose reduction should be considered when transitioning from home iGlar300 to iDet100 in the inpatient setting.PMID:35993253 | DOI:10.1177/10600280221119187 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 22, 2022 Category: Drugs & Pharmacology Authors: S D Wulfe K M Janzen J Addison D Kelley Source Type: research
